Psychedelic Business Models: Preparing For Clinical Trials And Commercialization

Following a years-long Big Pharma retreat from the discovery and development of new drugs for psychiatric and mental health disorders, an expanding group of psychedelic drug developers -- and interested investors -- hope to usher in a new golden age of psychedelic medicines. Life Science Leader is pleased to welcome executives representing three psychedelic drug companies to discuss their business models and the challenges unique to psychedelic drug development and commercialization.